FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200332645> ?p ?o ?g. }

• W3200332645 abstract "Abstract Background Concerns have been expressed about a number of drugs that potentially worsen outcomes in patients with COVID-19. We sought to identify all potentially deleterious drug groups in COVID-19 and critically assess the underpinning strength of evidence pertaining to the harmful effects of these drugs. Methods and findings We performed a rapid systematic review, searching Medline, Embase and two COVID-19 portfolios (WHO COVID-19 database and NIH iSearch COVID-19 portfolio) for papers and preprints related to primary studies investigating drugs identified as potentially deleterious. Primary outcomes were direct measures of susceptibility to infection, disease severity and mortality. Study quality was assessed using the National Heart, Lung, and Blood Institute quality assessment tools. Random-effects meta-analyses were used for data synthesis with further subgroup analyses where possible for specific outcome, study design, statistical adjustment and drug groups when two were combined. Sensitivity analyses were performed by removing any studies at high risk of bias and by publication status. 49 observational studies (15 peer-reviewed papers and 34 preprints) reported primary outcomes for eight drug groups hypothesised to be deleterious. Meta-analysis showed that acute inpatient corticosteroid use was associated with increased mortality (OR 2.22, 95% CI 1.26-3.90), however this result appeared to have been biased by confounding via indication. One subgroup analysis indicated an association between immunosuppressant use and susceptibility to COVID-19 among case control and cross-sectional studies (OR 1.29, 95% CI 1.19-1.40) but this was not found with cohort studies (OR 1.11, 95% CI 0.86-1.43). Studies which adjusted for multiple confounders showed that people taking angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin-II-receptor blockers (ARBs) required a lower level of care (OR 0.85, 95% CI 0.74-0.98). Furthermore, studies which combined these two drug groups in their analysis demonstrated an association with a lower mortality (OR 0.68, 95% CI 0.55-0.85). Conclusions We found minimal high quality or consistent evidence that any drug groups increase susceptibility, severity or mortality in COVID-19. Converse to initial hypotheses, we found some evidence that regular use of ACEIs and ARBs prior to infection may be effective in reducing the level of care required, such as requiring intensive care, in patients with COVID-19." @default.
• W3200332645 created "2021-09-27" @default.
• W3200332645 creator A5008771730 @default.
• W3200332645 creator A5016611652 @default.
• W3200332645 creator A5048677104 @default.
• W3200332645 creator A5066306728 @default.
• W3200332645 creator A5074135224 @default.
• W3200332645 date "2021-09-21" @default.
• W3200332645 modified "2023-09-27" @default.
• W3200332645 title "Deleterious drugs in COVID-19: a rapid systematic review and meta-analysis" @default.
• W3200332645 cites W1761831931 @default.
• W3200332645 cites W2028521865 @default.
• W3200332645 cites W2066073474 @default.
• W3200332645 cites W2108032575 @default.
• W3200332645 cites W2125750883 @default.
• W3200332645 cites W2165010366 @default.
• W3200332645 cites W2567362164 @default.
• W3200332645 cites W2746334579 @default.
• W3200332645 cites W3003217347 @default.
• W3200332645 cites W3005403371 @default.
• W3200332645 cites W3007829007 @default.
• W3200332645 cites W3008028633 @default.
• W3200332645 cites W3008589801 @default.
• W3200332645 cites W3009379198 @default.
• W3200332645 cites W3009799538 @default.
• W3200332645 cites W3009885589 @default.
• W3200332645 cites W3010426650 @default.
• W3200332645 cites W3011254885 @default.
• W3200332645 cites W3011558436 @default.
• W3200332645 cites W3011610993 @default.
• W3200332645 cites W3011885014 @default.
• W3200332645 cites W3012421327 @default.
• W3200332645 cites W3012615836 @default.
• W3200332645 cites W3013125498 @default.
• W3200332645 cites W3013231340 @default.
• W3200332645 cites W3013236891 @default.
• W3200332645 cites W3013393200 @default.
• W3200332645 cites W3013702546 @default.
• W3200332645 cites W3013789297 @default.
• W3200332645 cites W3013888222 @default.
• W3200332645 cites W3014147680 @default.
• W3200332645 cites W3014687026 @default.
• W3200332645 cites W3014972079 @default.
• W3200332645 cites W3015590289 @default.
• W3200332645 cites W3015696390 @default.
• W3200332645 cites W3016283232 @default.
• W3200332645 cites W3016358278 @default.
• W3200332645 cites W3016535995 @default.
• W3200332645 cites W3016553045 @default.
• W3200332645 cites W3016896832 @default.
• W3200332645 cites W3017267674 @default.
• W3200332645 cites W3017545174 @default.
• W3200332645 cites W3017577317 @default.
• W3200332645 cites W3019100529 @default.
• W3200332645 cites W3020049581 @default.
• W3200332645 cites W3020205604 @default.
• W3200332645 cites W3020519915 @default.
• W3200332645 cites W3020836354 @default.
• W3200332645 cites W3020853933 @default.
• W3200332645 cites W3021154562 @default.
• W3200332645 cites W3021366174 @default.
• W3200332645 cites W3021684016 @default.
• W3200332645 cites W3022450122 @default.
• W3200332645 cites W3022567999 @default.
• W3200332645 cites W3022602847 @default.
• W3200332645 cites W3023030876 @default.
• W3200332645 cites W3023640683 @default.
• W3200332645 cites W3023751598 @default.
• W3200332645 cites W3023971916 @default.
• W3200332645 cites W3024420022 @default.
• W3200332645 cites W3024732244 @default.
• W3200332645 cites W3025124391 @default.
• W3200332645 cites W3025283885 @default.
• W3200332645 cites W3032939692 @default.
• W3200332645 cites W3033263367 @default.
• W3200332645 cites W3036288118 @default.
• W3200332645 cites W3036806031 @default.
• W3200332645 cites W3047267821 @default.
• W3200332645 cites W3083738764 @default.
• W3200332645 cites W3092121807 @default.
• W3200332645 cites W3105949486 @default.
• W3200332645 cites W3130253221 @default.
• W3200332645 cites W3162283076 @default.
• W3200332645 cites W3165656738 @default.
• W3200332645 cites W3167347822 @default.
• W3200332645 cites W4205556411 @default.
• W3200332645 cites W4206620568 @default.
• W3200332645 cites W4294215472 @default.
• W3200332645 doi "https://doi.org/10.1101/2021.09.17.21262724" @default.
• W3200332645 hasPublicationYear "2021" @default.
• W3200332645 type Work @default.
• W3200332645 sameAs 3200332645 @default.
• W3200332645 citedByCount "0" @default.
• W3200332645 crossrefType "posted-content" @default.
• W3200332645 hasAuthorship W3200332645A5008771730 @default.
• W3200332645 hasAuthorship W3200332645A5016611652 @default.
• W3200332645 hasAuthorship W3200332645A5048677104 @default.
• W3200332645 hasAuthorship W3200332645A5066306728 @default.
• W3200332645 hasAuthorship W3200332645A5074135224 @default.
• W3200332645 hasBestOaLocation W32003326451 @default.

• next